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Abstract
Sifuvirtide is a proven effective HIV-1 entry inhibitor and its safety profile has been established for systemic administration.
The present study evaluated the potential of sifuvirtide formulated in a universal gel for topical use as a microbicide
candidate for preventing sexual transmission of HIV. Our data showed that sifuvirtide formulated in HEC gel is effective
against HIV-1 B, C subtypes, CRF07_BC and CRF01_AE, the latter two recombinants represents the most prevalent strains in
China. In addition, we demonstrated that sifuvirtide in gel is stable for at least 8 weeks even at 40uC, and did not cause the
disruption of integrity of mucosal epithelial surface, or the up-regulation of inflammatory cytokines both in vitro or in vivo.
These results suggest that sifuvirtide gel is an effective, safe and stable product, and should be further tested as a vaginal or
rectal microbicide in pre-clinical model or clinical trial for preventing HIV sexual transmission.
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Introduction
Recent report from Joint United Nations Programme on HIV/
AIDS (UNAIDS) showed that the global HIV-1 new infections
have declined by 19% in year 2010 compared with that in year
2009 [1]. Since the majority of new infections occur through
sexual intercourse, the use of microbicides applied to vaginal or
rectal mucosa is an important approach to prevent the sexual
transmission. Recently, the focus in microbicide development is
shifting from broad spectrum microbicide products with nonspe-
cific action mechanisms, such as surfactants or polyanions, to those
that can specifically inhibit HIV-1 infection, including reverse
transcriptase inhibitors (RTIs) [2,3]. A recent clinical trial showed
that 1% tenofovir (TFV), a gel version of the nucleotide reverse
transcriptase inhibitor (NRTI), provided moderate protection
against sexually transmitted HIV-1 [4], which for the first time
demonstrated that microbicide is a promising approach to restrain
HIV spreading.
HIV-1 infection could be dissected into multiple consecutive
steps, including binding, fusion, entry, reverse-transcription,
integration, transcription, translation and cleavage, assemble and
budding; Candidate drugs targeting procedures other than reverse
transcription are also likely to be effective if used as active
components in microbicide candidate. Similar to highly active
antiretroviral therapy (HAART), the most effective strategy for
microbicide development may need to combine several antiretro-
viral drugs targeting at different steps during HIV-1 life cycle.
Since HIV-1 viral entry is considered as an important target in
combating HIV/AIDS infections, several entry inhibitors specif-
ically blocking virus-cell attachment and fusion events have been
evaluated preclinically as potential microbicides, including CCR5
antagonists (e.g., maraviroc or PSC-RANTES), lectins (e.g.,
Cyanovirin-N or Griffithsin, both of which bind to mannose
moieties on HIV-1 gp120), and monoclonal antibodies (mAbs) that
inhibit HIV-1 binding or entry through binding to viral envelope
glycoprotein gp120, gp41, cellular receptor CD4 or coreceptor
CCR5 [2,3,5].
Sifuvirtide (SFT) is a new HIV-1 fusion inhibitor whose design
was based on the three-dimensional structure of the HIV-1 gp41
fusogenic core conformation [6–8]. In comparison with enfuvirtide
(T20), the only approved HIV-1 fusion inhibitor by the U.S. Food
and Drug Administration [9], SFT is more potent against
infections by a wide range of primary and laboratory-adapted
HIV-1 strains, including those resistant to T20 [8,10]. SFT also
exhibited good safety and tolerability in Phase Ia clinical study in
which volunteers were dosed by subcutaneous injection [8].
Therefore, SFT represents a promising active component for
microbicide development. Since SFT has not been tested for its
anti-HIV-1 efficacy and biosafety in a gel formation which will be
the case for the application in the genital tract or rectum as a
microbicide candidate, therefore, we formulated SFT with 1.5%
hydroxyethyl cellulose (HEC), a universal gel which has been used
in several vaginal gel formulations, and assessed its biosafety,
efficacy and stability; An universal placebo gel was also included in
parallel for evaluation [11]. The results showed that SFT in the gel
formulation exhibited equivalent anti-HIV-1 activities to SFT in
phosphate-buffered saline (PBS) solution in vitro, and SFT gel
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evaluation models. Consequently, these findings suggest the
potentials of SFT gel formulation for intravaginal or intrarectal
application as a microbicide to prevent the sexual transmission of
HIV-1.
Materials and Methods
Reagents
Nonoxynol-9 (N-9) (catalog# SLN1945) and cellulose sulfate
(CS) (catalog# SLC1798) were purchased from ScienceLab.com,
Inc. (Houston, Texas); k-Carrageenan (catalog# C1263) was
purchased from Sigma-Aldrich (St. Louis, MO) and TFV
(catalog# 14021945) was purchased from Molekula Limited
(Gillingham, Dorset, UK). Sifuvirtide (SFT) was provided by
FusoGen Pharmaceuticals, Inc. (Tianjin, China).
For in vitro experiments on cell lines, SFT was dissolved in sterile
PBS (pH=7.4) at indicated concentrations, to which hydroxyethyl
cellulose (HEC)(catalog# 434973, Sigma-Aldrich, St. Louis, MO)
was added (final concentration of HEC: 0.015%), followed by
continuously stirring for 45 min to allow all solutes to dissolve. For
in vivo application in mouse vagina, SFT, TFV, and N-9 were first
dissolved in PBS (pH=4.5) at indicated concentration, to which
HEC was slowly added to reach the final HEC concentration of
1.5% while the solution was rapidly stirred until a translucent gel
was formed [12]. We used 0.015% and 1.5% HEC gel for in vitro
and in vivo tests, respectively, based on an empirical rule [13,14]
that the concentration of the microbicide gel formation used in cell
culture in vitro should be diluted 100-fold from the concentration
used for in vivo test to facilitate the even spread of the product over
the cell culture and to avoid interference with the cell growth in
culture. . CS and k-Carrageenan were dissolved at indicated
concentration in pH 4.5 PBS without HEC to form gel
Figure 1. Efficacy of SFT gel against infections by HIV-1 pseudoviruses. (a) SFT is more effective in vitro against HIV-1 subtype C
pseudovirus than TFV. The IC50 value of TFV in PBS against subtype C was 5.2 mM, whereas that of SFT in PBS was only 25.6 nM. (b) Efficacy of SFT in
PBS or in 0.015% HEC gel to inhibit infection by HIV-1 pseudoviruses bearing the Env of CRF07_BC (upper left), CRF01_AE (upper right), B (lower left)
and C (lower right), respectively. Data represent means 6 SD from triplicate experiments. Student’s t-test was performed to determine the
significance of difference between various groups as shown in the graph, *p,0.05.
doi:10.1371/journal.pone.0037381.g001
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overnight at room temperature and were retested for pH before
intravaginal application as described below.
Cell Cultures
A human colorectal epithelial cell line, Caco-2, was kindly
provided by ATCC (USA) and was cultured in Dulbecco’s
Modified Eagle Medium (DMEM); TZM-bl cells and mouse
leukemic monocyte macrophage cell line RAW 264.7 were
purchased from the Cell Bank of Type Culture Collection of
Chinese Academy of Sciences and cultured in DMEM and RPMI
1640, respectively. All cell cultures were supplemented with 10%
fetal bovine serum (FBS), 2 mmol/L L-glutamine, 100 U/mL
penicillin, and 100 mg/mL streptomycin at 37uC/5% CO2.
HIV-1 pseudovirus infection inhibition assay
In the present study, we tested antiviral activity of SFT in PBS
or gel against viruses pseudotyped with Env of HIV-1 strains that
are predominantly circulating in China, HIV-1 subtype B and
subtype C. TFV, an NRTI that was proven in clinical trial to
reduce the risk of women acquiring HIV-1 infection by 39% [4],
was employed as a control. Briefly, four HIV-1 Env-pseudotyped
viruses were produced in 293T cells by co-transfection with the
expression plasmid encoding Envs of HIV-1 strains SVPB16
(subtype B), SVPC12 (subtype C), 32–72 (CRF07_BC), or
SH188.6 (CRF01_AE), respectively, and HIV-1 backbone plasmid
expressing the entire HIV-1 genome except Env, pNL4-3Denv
[15]. The pseudoviral particles were collected, titrated and stored
at 280uC until use. For viral inhibition assay, approximately
1610
4 TZM-bl cells per well were plated into a 96-well plate in
Figure 2. The content of SFT in HEC gel or PBS monitored by HPLC. (a) Representative chromatograms of SFT in 1.5% HEC and PBS. The
retention time was 14 min for SFT. (b) Percent of SFT recovery from the 1.5% HEC and PBS after 8 weeks of storage at 40uC (n=5, means 6 SD).
doi:10.1371/journal.pone.0037381.g002
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After culture at 37uC for one day, pseudoviruses (100 TCID50 per
well) were mixed with SFT or TFV in PBS solution or HEC gel
formulation at the indicated concentration, and then the mixtures
were added to the cells, followed by an incubation at 37uC with
5% CO2 for 48 h. The cells were then lysed in the presence of
Bright-Glo (Promega), and relative luminescence was recorded by
using a Victor 3 luminometer (PerkinElmer). The IC50 was then
calculated.
Accelerated stability study of SFT in microbicide gel
An accelerated stability study of SFT in microbicide gel was
conducted as previously described [16]. Briefly, SFT at 0.3 mM
was added into 1.5% HEC gel, and SFT-containing gel was stored
at 4uC, room temperature, 30uC and 40uC, respectively, in 75%
relative humidity (RH) for 1 to 8 weeks. Aliquots of samples were
taken out every week and diluted by PBS to 80 nM SFT (an IC90
value against HIV-1 subtype C) for testing their inhibitory activity
on HIV-1 pseudovirus subtype C infection, as described above. In
addition, the stability of SFT in the gel was further analyzed by
high-performance liquid chromatography (HPLC) on samples
stored at 40uC for up to 8 weeks. Their viscosity and pH profiles
were also determined as described below. The sample without
incubation at 40uC (0 week) was used as a control.
HPLC experiment
HPLC analysis of SFT peptide in gel were conducted on an
Agilent 1100 LC system (Agilent Technologies) with a reverse-phase
Ultra Aqueous C18 analytical column (2.1 mm6100 mm, 5 mm
particle size) and a guard column (2.1 mm612.5 mm, 5 mmp a r t i c l e
size) which were purchased fromAgilentCorporation. Samples were
diluted in 10% acetonitrile (ACN), 0.1% formicacid (FA). The LC
elution conditions were set as follows (all solvent percentages were
volume fractions): mobile phase A, 0.1% FA in water; mobile phase
B, 0.1% FA in ACN; time program, 0 min, 95% A/5% B; 1.0 min,
95% A/5% B; 10 min, 40% A/60% B; 12 min, 5% A/95% B;
15 min, 5% A/95% B; 16 min, 95% A/5% B; 25 min, 95% A/5%
B. The flow rate was 200 ml/min at ambient temperature. Column
oven temperature was 25uC. The detector was monitored with UV
detection at 215 nm. Peak area (PA) was calculated by Chemstation
software (Agilent Technologies) and recovery of SFT was calculated
as ‘‘PAsample of week8/PAsample of week06100’’.
Viscosity and pH determination of gel formulation
The viscosity of the gel formulations was measured by using a
NDJ-5S Rotational Viscometer (Wuxi Engin International Cor-
poration, Wuxi, China) with rotor #4 (60 rpm) at 25uC60.1uC.
The pH of the gels was determined at room temperature by using
a 423 microprobe electrode (Mettler Toledo Instruments,
Germany).
Table 1. An accelerated stability study of SFT in the gel formulation.
Intervals % Inhibition of HIV-1 infection
a
SFT in gel SFT in PBS
46CR T
b 306C4 0 6C4 6CR T 3 0 6C4 0 6C
Week 0 91.3460.84 89.7162.03 91.6360.38 94.1661.89 89.0961.97 88.2162.71 89.1562.76 88.8462.11
Week 1 80.5461.04 96.8461.15 92.0961.70 94.9162.88 94.6961.64 92.0861.23 92.6262.31 94.4861.41
Week 2 87.0560.87 93.9563.45 94.2662.63 88.2363.27 85.2160.94 89.5663.86 92.2062.57 86.3660.98
Week 3 89.7660.16 87.2861.88 89.5160.49 88.7762.35 88.7163.41 84.6461.47 90.6860.11 81.7364.66
Week 4 93.3360.95 96.2562.04 99.1060.35 99.2760.26 84.7760.87 81.8263.37 98.8260.95 87.9263.74
Week 5 93.8061.63 95.0361.69 93.9261.10 87.9262.72 92.6162.88 93.7962.43 90.5460.68 92.6761.24
Week 6 90.9960.44 93.4761.73 92.8161.65 87.8860.57 90.6161.36 88.0163.06 90.2062.16 88.8964.43
Week 7 93.2264.43 90.6461.70 89.6664.01 92.3261.02 93.1661.44 92.0661.01 93.6760.82 92.8061.80
Week 8 93.0260.77 91.3163.30 90.8864.58 82.7062.36 91.3061.54 90.8961.67 87.7664.09 91.3362.25
aData represent mean 6 SD (n=3).
bRT: room temperature.
doi:10.1371/journal.pone.0037381.t001
Table 2. Viscosity and pH profiles of SFT HEC gel stored at 40uC for 8 weeks.
Samples
Test HEC gel
a SFT HEC gel (0 week)
b SFT HEC gel (at 406C for 8 week)
b
Apearance Clear gel Clear gel Clear gel
pH 4.4160.020 4.5860.025 4.6360.056
Viscosity
c 5,800621.5 5,830618.9 5,810615.5
a1.5% HEC;
b0.3 mM SFT in 1.5% HEC;
cUnit: mPa.s; Samples were tested in triplicate and the data were represented in mean 6 SD.
doi:10.1371/journal.pone.0037381.t002
Sifuvirtide Gel as a Microbicide Candidate
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37381Figure 3. In vitro evaluation on the safety of SFT gel. (a) MTT assay was used to determine the cell viability of epithelial line Caco-2 (left) or
macrophage cell line RAW264.7 (right) after the treatment of different concentrations (3 nM, 30 nM and 300 nM) of SFT in PBS solution or
corresponding gel versions (formulated with 0.015% HEC). (b) Production of IL-6 (left) and TNF-a (right) in macrophage cell line RAW264.7 was
analyzed by CBA assay after incubation for 12 h with the above-mentioned three concentrations of SFT in PBS solutions or 0.015% HEC gel. Data
represent means 6SD from triplicate experiments. Student’s t-test was performed to determine the significance of difference between the PBS-
treated group and each microbicide candidate or LPS-treated groups, *p,0.05.
doi:10.1371/journal.pone.0037381.g003
Figure 4. Histopathological examination of vaginal tissues after intravaginal application of SFT gel and other microbicide
candidates. Slides were prepared from vaginal tissues treated with placebo (1.5% HEC gel) (a), 0.03 mM SFT gel (b), 0.3 mM SFT gel (c), 3 mM SFT
gel (d), 1% TFV gel (e), 3% carrageenan gel (f), 6% CS gel-treated group (g), or 1% N-9 gel-treated group (h). Hematoxylin-eosin staining was used for
all slides. Magnification, 6100.
doi:10.1371/journal.pone.0037381.g004
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The effect of SFT gel or SFT PBS solution on the viability of
Caco-2 cells or RAW264.7 cells was assessed by monitoring MTT
metabolism using a colorimetric assay of cell survival which was
carried out by the method of Denizot and Lang [17]. Briefly, cells
were seeded at 5610
4 ml
21 in 96-well flat-bottom microtiter
plates with different concentrations (3 nM, 30 nM and 300 nM) of
SFT in 0.015% HEC gel or in PBS solution. After an incubation
for 12 h at 37uC in a humidified 5% CO2,5 0ml of RAW264.7
cells in medium were sampled and stored at 280uC for further
cytokine quantification assay as described below. After continuous
incubation for 48 h, 10 ml of MTT (5 mg/ml) were added to the
plate and incubated for 4 h at 37uC. Afterwards, the medium was
removed, and the formazan, a product generated by the activity of
dehydrogenases in cells, was dissolved in acidified isopropanol (0.4
N HCl). The amount of MTT formazan is directly proportional to
the number of living cells and was determined by measuring the
optical density (OD) at 490 nm by using a Bio Assay reader
(BioRad, USA). The cell viability was calculated by the following
Figure 5. Inflammatory cytokines in CVLs after treatment of SFT gel and other microbicide candidates. Inflammatory cytokines,
including IL-6 (a), TNF-a (b), IFN-c (c), IL-10 (d) and IL-17A (e), were quantified in CVLs collected at 12 h post final dosage in the context of 3
consecutive days of intravaginal application of placebo (1.5% HEC), 0.03 mM SFT gel, 0.3 mM SFT gel, 3 mM SFT gel, 3% carrageenan gel, 1% TFV gel,
6% CS gel and 1% N-9 gel, respectively. The X-axis indicated the administration of different microbicide candidates; the Y-axis indicated the
production of corresponding inflammatory cytokines. Data represent means 6 SD from 5 mice per group. Student’s t-test was performed to
determine the significance of difference between the placebo gel control group and the treatment group for each microbicide candidate, *p,0.05.
doi:10.1371/journal.pone.0037381.g005
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carried out in triplicate.
Safety evaluation in mouse model in vivo
All animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) at
Shanghai Public Health Clinical Center and were performed in
accordance with relevant guidelines and regulations. Six- to eight-
week-old pathogen-free outbred BALB/c female mice were
purchased from Shanghai SLAC Laboratory Animal Co., Ltd.
(Shanghai, China). All mice were hormonally synchronized with
2 mg of medroxyprogesterone acetate (Catalog# M1629, Sigma-
Aldrich) 5 days prior to the treatment with candidate microbicides
[18,19]. For the in vivo safety study, mice randomized into eight
groups (5 mice/group) were intravaginally treated with 40 mlo f
1.5% HEC gel containing 0.03 mM SFT, 0.3 mM SFT, 3 mM
SFT, 1% N-9, 1% TFV, 6% CS, 3% carrageenan, or PBS (vehicle
control), respectively. The corresponding gel formulations were
then delivered intravaginally every 12 h (twice daily) for three
consecutive days. Twelve hours after the last treatment, cervico-
vaginal lavages (CVLs) were collected by washing the cervicov-
agina with 200 ml of sterile saline. The collected CVLs were
treated with protease inhibitor (Complete Protease Inhibitor
Cocktail; Catalog# 04693116001, Roche Applied Science,
Indianapolis, IN) and centrifuged at 2006g for 10 minutes at
4uC. Supernatants were then collected and stored at 280uC for
subsequent cytokine quantification assay. Finally, the mice were
sacrificed, and the vaginal tissues were collected for preparation of
mononuclear cells (MNCs) or for histological examination as
described below.
Histopathological examination
Formalin-fixed excised vaginal tissues were embedded within
paraffin and transversely sectioned with a microtome. The slides
were stained with hematoxylin-eosin and subjected to a blind
evaluation for epithelial cell disruption and inflammatory
responses.
Cytokine quantification assay
Cytokines from RAW264.7 cell culture supernatants or
cervicovaginal lavage fluid were determined by using a mouse
cytokine CBA kit (Catalog# 560485, BD Biosciences, California)
and analyzed on a FACSAria flow cytometer (BD Biosciences).
Tumor necrosis factor (TNF)-a, interleukin (IL)-6, interferon
(IFN)-c, IL-17A and IL-10 were included in the cytokine panel.
Standard curves were generated for each cytokine. Prior to
examination, the boundary was set from 0–5000 pg/ml, and the
lower detection limit for different analytes ranged from 0.03–
16.80 pg/ml, as described in manufacturer’s instructions.
Statistical analysis
Data are presented as the mean 6 standard deviation (SD).
Statistical significance between different groups was calculated by
the Student’s t-test using GraphPad Prism, version 5.0 (San Diego,
CA). Values of p,0.05 were considered statistically significant.
Results
SFT in gel formulation efficiently inhibit HIV infections in
vitro
In previous studies, SFT showed strong inhibitory activity
against a broad spectrum of HIV-1 strains, including those
resistant to T20, with IC50 ranged from 2.68 to 47.78 nM [8]. In
the present study, we showed that SFT was .200-fold more
potent than TFV against HIV-1 subtype C pseudovirus infection
(Figure 1a). The IC50 values of SFT in PBS against CRF07_BC,
CRF01_AE, subtype B and subtype C were 13.3, 30.9, 5.9 and
25.6 nM, respectively, while those for SFT in 0.015% HEC gel
were 9.8, 22.2, 3.4 and 12.4 nM, respectively (Figure 1b). These
data suggested that HEC might have slightly enhanced the anti-
HIV-1 efficacy of SFT in the gel. We and others have tested the
inhibitory activity of SFT against HIV-1 infection in peripheral
blood mononuclear cells (PBMCs) before and the results were well
comparable with those obtained from the experiments using from
TZM-bl cells [6,8], suggesting that SFT in HEC gel is expected to
be similarly effective against infection by primary HIV-1 isolates in
humans.
SFT formulated in HEC gel is stable
We tested the stability of SFT in HEC gel using an accelerated
stability assay. As shown in Table 1, the anti-HIV-1 efficacy of
SFT gels stored at the indicated temperatures was retained for up
to 8 weeks. We then used HPLC to monitor the content of intact
SFT in HEC gel and in PBS that were stored at 40uC for 8 weeks.
As shown in Figure 2, SFT HEC gel and SFT PBS solution, both
of which had been stored at 40uC for 8 weeks, exhibited the same
peak shape and retention time, compared with those freshly
prepared gels (0 week)(Figure 2a). The percent recovery of SFT at
the end of the eighth week of storage at 40uC was 99.72%62.18%
in the PBS solution and 100.31%61.84% in the HEC gel
(Figure 2b), suggesting that there is no significant drug loss or
generation of degradants after a sufficient period of time storage at
a relatively high temperature.
Additionally, several physical and chemical properties of the
SFT gel such as viscosity and pH in different conditions were also
monitored. As shown in Table 2, the addition of SFT did not
significantly change the viscosity of HEC gel. Furthermore, the
viscosity and pH value of SFT HEC gel formulation that was
stored at 40uC for was not changed remarkably. These results
indicate that SFT is stable in microbicide gel formation for a
sufficient period of time.
Biosafety profile of SFT in HEC gel formulation
We first performed in vitro safety evaluation by using a cell line
model. As shown in Figure 3a, both macrophage cell line
RAW264.7 and epithelial line Caco-2 retained ,100% viability
with treatment of SFT gel or SFT PBS solution after 48 h of
incubation, suggesting that neither SFT gel nor SFT PBS solution
causes significant cell death. To determine the potential proin-
flammatory effect of SFT gel, we used SFT gels or PBS solutions to
stimulate RAW264.7 cells for 12 h, respectively, and two
proinflammatory cytokines include TNF-a and IL-6 could be
detected in the cell culture supernatants. Compared to PBS
control, neither SFT gel nor SFT PBS solution induced additional
production of TNF-a or IL-6, whereas LPS (the positive control)
significantly elicited the secretion of TNF-a and IL-6. These
results suggest that both SFT PBS solution and SFT gel
formulation have no proinflammatory effect on the cultured
macrophage cells (Figure 3b).
To further investigate the biosafety of SFT gel on topical
mucosa, a mouse model was used for in vivo evaluation. We first
determined the impact of SFT gel on the integrity of mucosal
tissues. Histopathological examination displayed that HEC gel
alone-, TFV gel- and carrageenan gel-treated mice showed no
damage or inflammatory response in the cervicovaginal tissues
(Figure 4a, e, f), similarly, no obvious epithelial damage or
inflammatory response was observed in the cervicovaginal tissues
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treatment resulted in the disruption of epithelial cells and severe
inflammatory response (Figure 4h). CS gel-treated mouse tissues
displayed slight inflammatory response (Figure 4g).
We next determined the secretions of proinflammatory cyto-
kines triggered on topical mucosal sites by those microbicide
candidates mentioned above. While 1% TFV gel and 3%
carrageenan gel, which have been clinically proven as safe
microbicide formulations [4,11,20], did not induce any extra
secretion of the five cytokines comparing to HEC gel alone;
Similarly, 0.3 mM and 0.03 mM SFT gel also did not induce any
enhancement of the cytokine production compared to HEC gel;
3 mM SFT gel upregulated secretion of TNF-a but not other
cytokines. In contrast, 1% N-9 gel significantly upregulated the
production of TNF-a and IL-6, 6% CS gel increased the secretion
of TNF-a, IL-6, IL-10 and IFN-c (Figure 5). Taken together, SFT
gel has a potential to be developed as a safe and effective anti-HIV
microbicide for preventing sexual transmission of HIV.
Discussion
HIV-1 fusion/entry inhibitors, which target the initial step of
HIV-1 life cycle, are promising microbicide candidates. As known,
the mucus and the integrity of mucosal epithelial surface represent
two effective barriers for invasive pathogens and prevent the
occurrence of infections. It is believed that the disruption of the
integrity of mucosal epithelial surface and the mucosal topical
inflammation which could result in the enrichment of HIV-1
target cells and the dilution of vaginal mucus by ejected semen or
increased volume of vaginal fluid during the intercourse might
reduce the defense capabilities, thus facilitating HIV-1 spread
across the mucosal membrane to establish infection [21,22].
Therefore, the removal or disruption of those two barriers (the
undiluted mucus and the intact mucosa) may be required for HIV-
1 infection. It is rationalized that to build up the third barrier by
employing the HIV-1 entry inhibitor will be also highly effective to
block the invasion of HIV-1. Indeed, several entry inhibitors have
been employed in the microbicide development, including CCR5
antagonists (e.g., maraviroc or PSC-RANTES), lectins (e.g.,
Cyanovirin-N or Griffithsin, both of which bind to mannose
moieties on HIV-1 gp120), and several monoclonal antibodies that
could interrupt the binding between virus and target cells. Under
the consideration of building up the third barrier, large molecular
entry inhibitors may be preferentially selected because they may
be absorbed slowly and could extend their half-life at the mucosal
sites. Another advantage of the slowly absorbed molecule over the
rapidly absorbed drug as a microbicide is its slow absorption of the
drug into blood, thus causing less systemic toxic effect. Its
disadvantage is that under certain conditions, it may reach the
target cells beneath the epithelium after the virus.
SFT is a more potent large fusion/entry inhibitor against HIV-1
strains, including those resistant to T20, when compared to T20
[8], and is attractive to be used as active component in microbicide
candidate. In the present study, we investigated the anti-HIV-1
efficacy of SFT in a gel as formulated in microbicide, and showed
that SFT in HEC gel retained its potent anti-HIV-1 activities, not
only against subtype B or C, but also against CRF07_BC and
CRF01_AE which are predominantly circulating in China,
suggesting that it is likely that SFT would be effective when used
in populations in China and other regions as a gel formulation.
Since it is important for SFT to stabilize itself in vivo, we test the
stability of SFT in gel at or above body temperature, our data
showed that the SFT in gel could be stabilized for at least eight
weeks at the temperature as high as 40uC, indicating that this
product has the potential to stay at the mucosal site for a
prolonged period. However, the continuous exchange between
body fluid and mucosal surface and the possible appearance of
enzyme at the mucosal microenvironment may greatly reduce the
half-life of this product at the mucosal site. Our stability data are
also applicable for the storage and transportation of this product,
and indicated that this product will be much less dependent on
cold-chain, thereby reducing the cold-chain related costs.
The safety profile of a microbicide candidate should be carefully
evaluated before moving the candidate into clinical trial. As we
mentioned above, the removal of two natural barriers at mucosa
will increase the risk to acquire HIV-1 infection, therefore, anti-
HIV-1 microbicides should not cause the disruption of mucosa
integrity or inflammatory responses. Previous studies demonstrat-
ed that the systemic application of SFT was well tolerated without
any severe adverse events in Phase Ia clinical trial [8]. In the
present work, we evaluated the safety of SFT gel on topical
mucosal site by using both cell line and mouse models. Data
showed that SFT gel displayed good safety profiles in the in vitro
assay and caused no histopathological alterations to vaginal
epithelium in the mouse model. However, 3 mM SFT gel could
upregulate the secretion of TNF-a in CVLs, suggesting that SFT
concentrations over 3 mM should be excluded in further
preclinical (e.g., evaluation by rhesus model) or clinical evalua-
tions. Intriguingly, TNF-a was observed to be the cytokine most
commonly and significantly upregulated, irrespective of treatment
compound (N-9, CS or 3 mM SFT), suggesting that TNF-a is a
sensitive and general inflammation marker to evaluate mucosal
toxicity induced by different microbicide candidates.
Overall, the present study provides evidences that the SFT gel is
a promising vaginal microbicide candidate and could be employed
to build up the third barrier at the mucosal site. Though it is
speculated that SFT may possess a prolonged half-life in vivo,a
real-time monitoring will be required to determine its pharmaco-
kinetics. In addition, SFT as an entry inhibitor is likely to exert its
synergistic effect with other classes of antiretroviral drugs, such as
reverse transcriptase inhibitor and protease inhibitor, and thereby
be employed in the development of more potent microbicide
candidate.
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